Last reviewed · How we verify

Xeglyze — Competitive Intelligence Brief

Xeglyze (ABAMETAPIR) competitive landscape: 4 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Area: Other.

marketed C-C chemokine receptor type 5 Other Small molecule Live · refreshed every 30 min

Target snapshot

Xeglyze (ABAMETAPIR) — Hatchtech.

Comparator set (4 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Xeglyze TARGET ABAMETAPIR Hatchtech marketed C-C chemokine receptor type 5 2020-01-01
Selzentry MARAVIROC GSK marketed CCR5 Co-receptor Antagonist [EPC] C-C chemokine receptor type 5 2007-01-01
Selzentry Selzentry Icahn School of Medicine at Mount Sinai marketed Multidrug and toxin extrusion protein 1, C-C chemokine receptor type 5, C-C chemokine receptor type 5
Maraviroc (MVC) Maraviroc (MVC) National Institute of Allergy and Infectious Diseases (NIAID) marketed CCR5 antagonist CCR5 (C-C chemokine receptor type 5)
Maraviroc (Celsentri) Maraviroc (Celsentri) ANRS, Emerging Infectious Diseases phase 3 CCR5 antagonist CCR5 (C-C chemokine receptor type 5)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape

No sponsor landscape data.

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Xeglyze — Competitive Intelligence Brief. https://druglandscape.com/ci/abametapir. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators: